Axichem Pty Ltd

Chemwatch: 26-0743 Version No: 9.1

Safety Data Sheet according to WHS Regulations (Hazardous Chemicals) Amendment 2020 and ADG requirements

Chemwatch Hazard Alert Code: 3

Issue Date: **27/10/2023**Print Date: **16/02/2024**L.GHS.AUS.EN

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product Identifier

Product name	AC Tussel
Chemical Name	Not Applicable
Synonyms	Not Available
Proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (contains clodinafop-propargyl)
Chemical formula	Not Applicable
Other means of identification	Not Available

Relevant identified uses of the substance or mixture and uses advised against

Polovant	identified	11606	Herbicide.
Relevant	iaentifiea	uses	Herbiciae.

Details of the manufacturer or supplier of the safety data sheet

Registered company name	Axichem Pty Ltd
Address	9 Palings Court Nerang QLD 4211 Australia
Telephone	07 5596 1736
Fax	Not Available
Website	www.axichem.com.au
Email	msds@axichem.com.au

Emergency telephone number

Association / Organisation	CHEMWATCH EMERGENCY RESPONSE (24/7)
Emergency telephone numbers	+61 1800 951 288
Other emergency telephone numbers	+61 3 9573 3188

Once connected and if the message is not in your preferred language then please dial 01

SECTION 2 Hazards identification


Classification of the substance or mixture

COMBUSTIBLE LIQUID, regulated for storage purposes only

Poisons Schedule	S6
Classification ^[1]	Flammable Liquids Category 4, Acute Toxicity (Oral) Category 4, Aspiration Hazard Category 1, Skin Corrosion/Irritation Category 2, Sensitisation (Skin) Category 1, Serious Eye Damage/Eye Irritation Category 2A, Specific Target Organ Toxicity - Repeated Exposure Category 2, Hazardous to the Aquatic Environment Acute Hazard Category 2, Hazardous to the Aquatic Environment Long-Term Hazard Category 2
Legend:	1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI

Label elements

Issue Date: 27/10/2023 Print Date: 16/02/2024









Signal word

Danger

Hazard statement(s)

H227	Combustible liquid.
H302	Harmful if swallowed.
H304	May be fatal if swallowed and enters airways.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H373	May cause damage to organs through prolonged or repeated exposure.
H411	Toxic to aquatic life with long lasting effects.

Precautionary statement(s) Prevention

P210	Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
P260	Do not breathe mist/vapours/spray.
P280	Wear protective gloves, protective clothing, eye protection and face protection.
P264	Wash all exposed external body areas thoroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P273	Avoid release to the environment.
P272	Contaminated work clothing should not be allowed out of the workplace.

Precautionary statement(s) Response

P301+P310	IF SWALLOWED: Immediately call a POISON CENTER/doctor/physician/first aider.
P331	Do NOT induce vomiting. If more than 15 mins from Doctor, INDUCE VOMITING (if conscious).
P370+P378	In case of fire: Use alcohol resistant foam or normal protein foam to extinguish.
P302+P352	IF ON SKIN: Wash with plenty of water.
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P314	Get medical advice/attention if you feel unwell.
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
P337+P313	If eye irritation persists: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before reuse.
P391	Collect spillage.
P301+P312	IF SWALLOWED: Call a POISON CENTER/doctor/physician/first aider if you feel unwell.
P330	Rinse mouth.

Precautionary statement(s) Storage

P403	Store in a well-ventilated place.
P405	Store locked up.

Precautionary statement(s) Disposal

P501 Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
105512-06-9	>24	<u>clodinafop-propargyl</u>
99607-70-2	>6	cloquintocet-mexyl
872-50-4	<10	N-methyl-2-pyrrolidone
64742-95-6.	<10	aromatic 150
Not Available	>10	ingredients non-hazardous
Legend: 1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L * EU IOELVs available		

SECTION 4 First aid measures

Description of first aid measures

Eye Contact	If this product comes in contact with the eyes: • Wash out immediately with fresh running water. • Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. • Seek medical attention without delay; if pain persists or recurs seek medical attention. • Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	If skin contact occurs: Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation.
Inhalation	 If fumes, aerosols or combustion products are inhaled remove from contaminated area. Other measures are usually unnecessary.
Ingestion	 For advice, contact a Poisons Information Centre or a doctor. If swallowed do NOT induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. Observe the patient carefully. Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. Seek medical advice.

Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

Any material aspirated during vomiting may produce lung injury. Therefore emesis should not be induced mechanically or pharmacologically. Mechanical means should be used if it is considered necessary to evacuate the stomach contents; these include gastric lavage after endotracheal intubation. If spontaneous vomiting has occurred after ingestion, the patient should be monitored for difficult breathing, as adverse effects of aspiration into the lungs may be delayed up to 48 hours.

SECTION 5 Firefighting measures

Extinguishing media

- Water spray or fog.
- Dry chemical powder.
- ▶ BCF (where regulations permit).
- Carbon dioxide.

Special hazards arising from the substrate or mixture

Fire Incompatibility

Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may

Advice for firefighters

▶ Alert Fire Brigade and tell them location and nature of hazard.

- Wear breathing apparatus plus protective gloves.
- Prevent, by any means available, spillage from entering drains or water courses.
- ▶ Use water delivered as a fine spray to control fire and cool adjacent area.
- Fire Fighting ▶ DO NOT approach containers suspected to be hot.
 - Cool fire exposed containers with water spray from a protected location.
 - If safe to do so, remove containers from path of fire.

Issue Date: 27/10/2023 Version No: 9.1 Print Date: 16/02/2024 **AC Tussel**

	► Equipment should be thoroughly decontaminated after use.
Fire/Explosion Hazard	 Combustible. Slight fire hazard when exposed to heat or flame. Heating may cause expansion or decomposition leading to violent rupture of containers. On combustion, may emit toxic fumes of carbon monoxide (CO). May emit acrid smoke. Mists containing combustible materials may be explosive. Combustion products include: carbon dioxide (CO2) hydrogen chloride phosgene hydrogen fluoride nitrogen oxides (NOx) other pyrolysis products typical of burning organic material.
HAZCHEM	•3Z

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

Minor Spills	Environmental hazard - contain spillage. Premove all ignition sources. Clean up all spills immediately. Avoid breathing vapours and contact with skin and eyes. Control personal contact with the substance, by using protective equipment. Contain and absorb spill with sand, earth, inert material or vermiculite. Wipe up. Place in a suitable, labelled container for waste disposal.
Major Spills	Environmental hazard - contain spillage. Moderate hazard. Clear area of personnel and move upwind. Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves. Prevent, by any means available, spillage from entering drains or water course. No smoking, naked lights or ignition sources. Increase ventilation. Stop leak if safe to do so. Contain spill with sand, earth or vermiculite. Collect recoverable product into labelled containers for recycling. Absorb remaining product with sand, earth or vermiculite. Collect solid residues and seal in labelled drums for disposal. Wash area and prevent runoff into drains. If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling

 DO NOT allow clothing wet with material to stay in contact with skin Avoid all personal contact, including inhalation. Wear protective clothing when risk of exposure occurs. Use in a well-ventilated area. Prevent concentration in hollows and sumps. DO NOT enter confined spaces until atmosphere has been checked. Avoid smoking, naked lights or ignition sources. Avoid contact with incompatible materials. When handling, DO NOT eat, drink or smoke. Keep containers securely sealed when not in use. Avoid physical damage to containers. Always wash hands with soap and water after handling. 		3
	Safe handling	 Avoid all personal contact, including inhalation. Wear protective clothing when risk of exposure occurs. Use in a well-ventilated area. Prevent concentration in hollows and sumps. DO NOT enter confined spaces until atmosphere has been checked. Avoid smoking, naked lights or ignition sources. Avoid contact with incompatible materials. When handling, DO NOT eat, drink or smoke. Keep containers securely sealed when not in use. Avoid physical damage to containers.

Issue Date: **27/10/2023**Print Date: **16/02/2024**

	 Work clothes should be laundered separately. Use good occupational work practice. Observe manufacturer's storage and handling recommendations contained within this SDS. Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions.
Other information	 Store in original containers. Keep containers securely sealed. No smoking, naked lights or ignition sources. Store in a cool, dry, well-ventilated area. Store away from incompatible materials and foodstuff containers. Protect containers against physical damage and check regularly for leaks. Observe manufacturer's storage and handling recommendations contained within this SDS.

Conditions for safe storage, including any incompatibilities

Suitable container	 Metal can or drum Packaging as recommended by manufacturer. Check all containers are clearly labelled and free from leaks. 	
Storage incompatibility	Avoid reaction with oxidising agents	

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure	N-methyl-	1-Methyl-	25 ppm / 103	309 mg/m3 / 75	Not	Not
Standards	2-pyrrolidone	2-pyrrolidone	mg/m3	ppm	Available	Available

Emergency Limits

Ingredient	TEEL-1	TEEL-2	TEEL-3
N-methyl-2-pyrrolidone	30 ppm	32 ppm	190 ppm
aromatic 150	1,200 mg/m3	6,700 mg/m3	40,000 mg/m3

Ingredient	Original IDLH	Revised IDLH
clodinafop-propargyl	Not Available	Not Available
cloquintocet-mexyl	Not Available	Not Available
N-methyl-2-pyrrolidone	Not Available	Not Available
aromatic 150	Not Available	Not Available

Occupational Exposure Banding

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit
clodinafop-propargyl	E	≤ 0.01 mg/m³
cloquintocet-mexyl	D	> 0.01 to ≤ 0.1 mg/m³
aromatic 150	E	≤ 0.1 ppm
Notes:	Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.	

MATERIAL DATA

None assigned. Refer to individual constituents.

NOTE P: The classification as a carcinogen need not apply if it can be shown that the substance contains less than 0.01% w/w benzene (EINECS No 200-753-7). Note E shall also apply when the substance is classified as a carcinogen. This note applies only to certain complex oil-derived substances in Annex VI. European Union (EU) List of harmonised classification and labelling hazardous substances, Table 3.1, Annex VI, Regulation (EC) No 1272/2008 (CLP) - up to the latest ATP

Exposure controls

Appropriate engineering
controls

Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection.

The basic types of engineering controls are:

Chemwatch: 26-0743 Version No: 9.1 Page 6 of 17

AC Tussel

Issue Date: **27/10/2023**Print Date: **16/02/2024**

Process controls which involve changing the way a job activity or process is done to reduce the risk.

Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use. Employers may need to use multiple types of controls to prevent employee overexposure.

General exhaust is adequate under normal operating conditions. Local exhaust ventilation may be required in specific circumstances. If risk of overexposure exists, wear approved respirator. Correct fit is essential to obtain adequate protection. Provide adequate ventilation in warehouse or closed storage areas. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant

Type of Contaminant:	Air Speed:
solvent, vapours, degreasing etc., evaporating from tank (in still air).	0.25-0.5 m/s (50-100 f/min)
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)
direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min.)
grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).	2.5-10 m/s (500-2000 f/min.)

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2 m/s (200-400 f/min) for extraction of solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

Individual protection measures, such as personal protective equipment









Safety glasses with side shields.

- ► Chemical goggles. [AS/NZS 1337.1, EN166 or national equivalent]
- Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].

Hands/feet protection

Skin protection

Eye and face protection

See Hand protection below

- Wear chemical protective gloves, e.g. PVC.
- Wear safety footwear or safety gumboots, e.g. Rubber

NOTE:

- The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact.
- ▶ Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed.

The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.

The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final choice.

Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include:

- · frequency and duration of contact,
- · chemical resistance of glove material,
- · glove thickness and

dexterity

Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent).

- · When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.
- · When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.
- · Some glove polymer types are less affected by movement and this should be taken into account when considering gloves for long-term use.
- \cdot Contaminated gloves should be replaced.

As defined in ASTM F-739-96 in any application, gloves are rated as:

- · Excellent when breakthrough time > 480 min
- · Good when breakthrough time > 20 min
- · Fair when breakthrough time < 20 min
- · Poor when glove material degrades

For general applications, gloves with a thickness typically greater than 0.35 mm, are recommended.

It should be emphasised that glove thickness is not necessarily a good predictor of glove resistance to a specific chemical, as the permeation efficiency of the glove will be dependent on the exact composition of the glove material. Therefore, glove selection should also be based on consideration of the task requirements and knowledge of breakthrough times.

Glove thickness may also vary depending on the glove manufacturer, the glove type and the glove model. Therefore, the manufacturers technical data should always be taken into account to ensure selection of the most appropriate glove for the task. Note: Depending on the activity being conducted, gloves of varying thickness may be required for specific tasks. For example:

- Thinner gloves (down to 0.1 mm or less) may be required where a high degree of manual dexterity is needed. However, these gloves are only likely to give short duration protection and would normally be just for single use applications, then disposed of.
- · Thicker gloves (up to 3 mm or more) may be required where there is a mechanical (as well as a chemical) risk i.e. where there is abrasion or puncture potential

Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

Body protection

See Other protection below

Other protection

- Overalls.
- P.V.C apron.
- ▶ Barrier cream.
- Skin cleansing cream.
- ▶ Eye wash unit.

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the *computer-generated* selection:

AC Tussel

Material	СРІ
BUTYL	A
PE/EVAL/PE	A
NATURAL RUBBER	В
PVA	В

* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Respiratory protection

Type AK-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 5 x ES	AK-AUS / Class 1 P3	-	AK-PAPR-AUS / Class 1 P3
up to 25 x ES	Air-line*	AK-2 P3	AK-PAPR-2 P3
up to 50 x ES	-	AK-3 P3	-
50+ x ES	-	Air-line**	-

^ - Full-face

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

Appearance Light to dark brown liquid with aromatic solvent odour; emulsifiable with water.

Physical state

Liauid

Relative density (Water =

1.06-1.10

1)

	1		1
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Available	Decomposition temperature (°C)	Not Available
Melting point / freezing point (°C)	<-10	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	>70	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Combustible.	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Available	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available
Solubility in water	Miscible	pH as a solution (1%)	Not Available
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available

SECTION 10 Stability and reactivity

Reactivity	See section 7	
Chemical stability	 Unstable in the presence of incompatible materials. Product is considered stable. Hazardous polymerisation will not occur. 	
Possibility of hazardous reactions	See section 7	
Conditions to avoid	See section 7	
Incompatible materials	See section 7	
Hazardous decomposition products	See section 5	

SECTION 11 Toxicological information

Information on toxicological effects

Inhaled	The material is not thought to produce adverse health effects or irritation of the respiratory tract (as classified by EC Directives using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.
Ingestion	Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual. Swallowing of the liquid may cause aspiration of vomit into the lungs with the risk of haemorrhaging, pulmonary oedema, progressing to chemical pneumonitis; serious consequences may result. Signs and symptoms of chemical (aspiration) pneumonitis may include coughing, gasping, choking, burning of the mouth, difficult breathing, and bluish coloured skin (cyanosis).
Skin Contact	Evidence exists, or practical experience predicts, that the material either produces inflammation of the skin in a substantial number of individuals following direct contact, and/or produces significant inflammation when applied to the healthy intact skin of animals, for up to four hours, such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis. The material may accentuate any pre-existing dermatitis condition Skin contact is not thought to have harmful health effects (as classified under EC Directives); the material may still produce health damage following entry through wounds, lesions or abrasions. Open cuts, abraded or irritated skin should not be exposed to this material Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.
Eye	Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals.

Chronic

AC Tussel

Issue Date: **27/10/2023**Print Date: **16/02/2024**

Repeated or prolonged eye contact may cause inflammation characterised by temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.

Practical experience shows that skin contact with the material is capable either of inducing a sensitisation reaction in a substantial number of individuals, and/or of producing a positive response in experimental animals.

Substances that can cause occupational asthma (also known as asthmagens and respiratory sensitisers) can induce a state of specific airway hyper-responsiveness via an immunological, irritant or other mechanism. Once the airways have become hyper-responsive, further exposure to the substance, sometimes even to tiny quantities, may cause respiratory symptoms. These symptoms can range in severity from a runny nose to asthma. Not all workers who are exposed to a sensitiser will become hyper-responsive and it is impossible to identify in advance who are likely to become hyper-responsive.

Substances than can cuase occupational asthma should be distinguished from substances which may trigger the symptoms of asthma in people with pre-existing air-way hyper-responsiveness. The latter substances are not classified as asthmagens or respiratory sensitisers

Wherever it is reasonably practicable, exposure to substances that can cuase occupational asthma should be prevented. Where this is not possible the primary aim is to apply adequate standards of control to prevent workers from becoming hyperresponsive.

Activities giving rise to short-term peak concentrations should receive particular attention when risk management is being considered. Health surveillance is appropriate for all employees exposed or liable to be exposed to a substance which may cause occupational asthma and there should be appropriate consultation with an occupational health professional over the degree of risk and level of surveillance.

Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.

	TOXICITY	IRRITATION
AC Tussel	Dermal (Rat) LD50: >4000 mg/kg ^[2]	Not Available
AC TUSSEI	Inhalation (Rat) LC50: >3500 mg/m3/4h ^[2]	
	Oral (Rat) LD50: >2276 mg/kg ^[2]	
	TOXICITY	IRRITATION
ala Paratan nananan d	dermal (rat) LD50: >2000 mg/kg ^[2]	Eye (rabbit): non-irritating *
clodinafop-propargyl	Inhalation(Rat) LC50: 2.325 mg/l4h ^[2]	Skin (rabbit): non-irritating *
	Oral (Rat) LD50: 1829 mg/kg ^[2]	
	TOXICITY	IRRITATION
ala muinta ant manud	dermal (rat) LD50: >2000 mg/kg ^[2]	Eye (rabbit): non-irritating *
cloquintocet-mexyl	Inhalation(Rat) LC50: >0.935 mg/L4h ^[2]	Skin (rabbit): non-irritating **
	Oral (Rat) LD50: >2000 mg/kg ^[2]	
	TOXICITY	IRRITATION
Name that O assume Pales as	Dermal (rabbit) LD50: 8000 mg/kg ^[2]	Eye (rabbit): 100 mg - moderate *[Manufacturer]
N-methyl-2-pyrrolidone	Inhalation(Rat) LC50: 3.1-8.8 mg/l4h ^[2]	
	Oral (Rat) LD50: 3914 mg/kg ^[2]	
	TOXICITY	IRRITATION
	Dermal (rabbit) LD50: >1900 mg/kg ^[1]	Eye: no adverse effect observed (not irritating)[1]
aromatic 150	Inhalation(Rat) LC50: >4.42 mg/L4h ^[1]	Skin: adverse effect observed (irritating) ^[1]
	Oral (Rat) LD50: >4500 mg/kg ^[1]	

Legend:

1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2. Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances

AC Tussel

[for almost identical formulation, Manufacturer]

Toxicity Class WHO III * NOEL (3 month) 0.9 mg/kg b.w. daily ADI: 0.004 mg/kg/day

ACCase plays a vital role in mammalian systems for fatty acid biosynthesis, the enzyme existing in two isozymic forms. This enzyme is highly regulated in the brain and non-neural tissue. None of these forms are inhibited by cyclohexanediones or aryloxyphenoxypropionates. Although these herbicides affect common target sites in plants and mammals, they have no effect on ACCase in mammals.

CLODINAFOP-PROPARGYL

for quizalofop-p-ethyl (as a representative of the aryloxyphenoxypropionate group of herbicides):

Acute toxicity: Quizalofop-p-ethyl is nonirritating to the skin and only slightly irritating to the eyes in rabbits It is nonsensitising to the skin of guinea pigs

Chronic toxicity: In a 1-year feeding study on dogs, doses of up to 10 mg/kg/day quizalofop-p-ethyl (the highest dose tested in that study) caused no observed effects. In a 90-day feeding study in rats, doses of 6.4 mg/kg/day and higher produced liver

Issue Date: **27/10/2023**Print Date: **16/02/2024**

lesions and increased liver weight

In a 2-year feeding study conducted with rats with the racemic mixture of quizalofop-p-ethyl isomers the no-observable-effect level (NOEL) was 25 ppm (1.25 mg/kg/day) based on liver effects which occurred at 100 ppm. There was a slight but non-significant increase in female liver tumours at 400 ppm. The material was non-oncogenic in this species. In an 18 month feeding study with mice the NOEL was 10 ppm (1.5 mg/kg/day) based on effects on liver and testes at 80 ppm. An increase in liver carcinomas was observed in male mice and an increased incidence of ovarian tumours (leuteomas and granulosa cell tumour)s were observed in female mice. These effects were statistically significant at 320 ppm (48 mg/kg/day). In a 1-year feeding study with dogs the NOEL was 400 mg (30 mg/kg/day) with no compound related effects apparent.

Reproductive toxicity: Data from reproductive studies indicated only decreased body weight gains, and did not report findings of impaired reproductive function in test animals A 6-month study in dogs found atrophy of the semeniferous tubules at doses of 2.5 mg/kg/day, but was unclear whether this was extensive enough to result in impaired reproductive function. These data are insufficient to draw conclusions regarding the likely reproductive effects of quizalofop-p-ethyl in animals, but suggest that effects on human reproduction are unlikely under normal circumstances

In a reproductive study conducted with rats, parents and off-spring showed body weight decreases at 400 ppm. Histological changes in liver were observed at 100 ppm. The NOEL was 25 ppm (approximately 1.25 mg/kg/day).

Developmental toxicity: In teratogenic studies there was no evidence of teratogenicity or embryotoxicity at levels up to 60 mg/kg/day. Body weight gain and other toxic effects were seen in pregnant rabbits at 60 mg/kg/day. Overall NOEL was 30 mg/kg/day. The product was not teratogenic to rats at dose levels of up to 300 mg/kg/day. Reduced body weight gains were evident in dams at 300 mg/kg. Offspring of this treatment group exhibited reduced survival and a transient increase in skeletal variations. The NOEL for this group was 30 mg/kg/day.

Genotoxicity: The results of many assays for mutagenicity and genotoxicity of quizalofop-p-ethyl show no mutagenic or genotoxic activity Negative results were obtained in the Ames and Chinese hamster ovary (CHO) test for gene mutation, the CHO and mouse micronucleus tests for chromosomal aberration, DNA repair assays in B.subtilis and rat liver cells, and sister chromated exchange assay in Chinese hamster cells.

Carcinogenic effects: In an 18-month carcinogenicity study on mice, increased liver weights, changes in blood chemistry, and some changes in liver tissue structure were detected, but no carcinogenic or tumor-causing activity was reported. This study suggests that this compound is not carcinogenic.

Organ toxicity: Available data show that the target organ in test animals has consistently been the liver in rats and dogs [8]. It is possible that testes may be a target organ in some species; e.g., dogs.

Fate in humans and animals: Quizalofop-p appears to be rapidly broken down in mammals. More than 90% of a single oral dose is eliminated in urine within 3 days

Inhibitors of acetyl CoA carboxylase, the target enzyme of certain herbicides, have the capacity, in mammals, to alter blood lipid levels. In the male rat, a reduction (p < 0.05) in blood cholesterol and total lipids in a chronic study may be a reflection of inhibition of this enzyme. However, in the female mouse, there was an increase in blood cholesterol at the highest dose tested, in a subchronic study. Male mice in this study showed an increase in total lipids at the two highest doses. It is therefore possible that many of the effects reported in acute, subchronic and chronic studies are manifestations of a compromise of normal liver function. The inhibition of fatty acid biosynthesis, in the liver. may account for the majority of the effects observed. However, increases in liver weight, seen in acute and sub-chronic studies, and decreases in liver weight, which are seen in chronic studies, alone, do not necessarily reflect an adverse effect. This is because liver weight changes have often been found to be reversible, in subchronic studies following the discontinuation of dosing, or through adaptation mechanisms, with the continued dietary intake of fenoxaprop-ethyl. in chronic studies.

[* The Pesticides Manual, Incorporating The Agrochemicals Handbook, 10th Edition, Editor Clive Tomlin, 1994, British Crop Protection Council]

CLOQUINTOCET-MEXYL

*Merck Index NOEL (2 y) for rats 4 mg/kg b.w. daily; (18 mo) for mice 106.5 mg/kg b.w. daily; (1 y) 44 mg/kg b.w. daily ADI 0.04 mg/kg b.w. Toxicity Class WHO (a.i.) III Cloquintocet-mexyl technical has been extensively tested and no evidence of mutagenic, carcinogenic, teratogenic, or reproductive effects was obtained.

for N-methyl-2-pyrrolidone (NMP):

Acute toxicity: In rats, NMP is absorbed rapidly after inhalation, oral, and dermal administration, distributed throughout the organism, and eliminated mainly by hydroxylation to polar compounds, which are excreted via urine. About 80% of the administered dose is excreted as NMP and NMP metabolites within 24 h. A probably dose-dependent yellow coloration of the urine in rodents is observed. The major metabolite is 5-hydroxy-*N*-methyl-2-pyrrolidone.

Studies in humans show comparable results. Dermal penetration through human skin has been shown to be very rapid. NMP is rapidly biotransformed by hydroxylation to 5-hydroxy-*N*-methyl-2-pyrrolidone, which is further oxidized to *N*-methylsuccinimide; this intermediate is further hydroxylated to 2-hydroxy-*N*-methylsuccinimide. These metabolites are all colourless. The excreted amounts of NMP metabolites in the urine after inhalation or oral intake represented about 100% and 65% of the administered doses, respectively.

NMP has a low potential for skin irritation and a moderate potential for eye irritation in rabbits. Repeated daily doses of 450 mg/kg body weight administered to the skin caused painful and severe haemorrhage and eschar formation in rabbits. These adverse effects have not been seen in workers occupationally exposed to pure NMP, but they have been observed after dermal exposure to NMP used in cleaning processes. No sensitisation potential has been observed.

In acute toxicity studies in rodents, NMP showed low toxicity. Uptake of oral, dermal, or inhaled acutely toxic doses causes functional disturbances and depressions in the central nervous system. Local irritation effects were observed in the respiratory tract when NMP was inhaled and in the pyloric and gastrointestinal tracts after oral administration. In humans, there was no irritative effect in the respiratory system after an 8-h exposure to 50 mg/m3.

Repeat dose toxicity: There is no clear toxicity profile of NMP after multiple administration. In a 28-day dietary study in rats, a compound-related decrease in body weight gain was observed in males at 1234 mg/kg body weight and in females at 2268 mg/kg body weight. Testicular degeneration and atrophy in males and thymic atrophy in females were observed at these dose levels. The no-observed-adverse-effect level (NOAEL) was 429 mg/kg body weight in males and 1548 mg/kg body weight in females. In a 28-day intubation study in rats, a dose-dependent increase in relative liver and kidney weights and a decrease in lymphocyte count in both sexes were observed at 1028 mg/kg body weight. The NOAEL in this study was 514 mg/kg body weight. In another rat study, daily dietary intake for 90 days caused decreased body weights at doses of 433 and 565 mg/kg body weight in males and females, respectively. There were also neurobehavioural effects at these dose levels. The NOAELs in males

N-METHYL-2-PYRROLIDONE

Issue Date: **27/10/2023**Print Date: **16/02/2024**

and females were 169 and 217 mg/kg body weight, respectively.

The toxicity profile after exposure to airborne NMP depends strongly on the ratio of vapour to aerosol and on the area of exposure (i.e., head-only or whole-body exposure). Because of higher skin absorption for the aerosol, uptake is higher in animals exposed to aerosol than in those exposed to vapour at similar concentrations. Studies in female rats exposed head only to 1000 mg/m3 showed only minor nasal irritation, but massive mortality and severe effects on major organs were observed when the females were whole-body exposed to the same concentration of coarse droplets at high relative humidity. Several studies in rats following repeated exposure to NMP at concentrations between 100 and 1000 mg/m3 have shown systemic toxicity effects at the lower dose levels. In most of the studies, the effects were not observed after a 4-week observation period.

In rats, exposure to 3000 mg NMP/m3 (head only) for 6 h/day, 5 days/week, for 13 weeks caused a decrease in body weight gain, an increase in erythrocytes, haemoglobin, haematocrit, and mean corpuscular volume, decreased absolute testis weight, and cell loss in the germinal epithelium of the testes. The NOAEL was 500 mg/m3.

There are no data in humans after repeated-dose exposure.

Carcinogenicity: NMP did not show any clear evidence for carcinogenicity in rats exposed to concentrations up to 400 mg/m3 in a long-term inhalation study.

Genotoxicity: The mutagenic potential of NMP is weak. Only a slight increase in the number of revertants was observed when tested in a *Salmonella* assay with base-pair substitution strains. NMP has been shown to induce aneuploidy in yeast *Saccharomyces cerevisiae* cells. No investigations regarding mutagenicity in humans were available.

Reproductive toxicity: In a two-generation reproduction study in rats, whole-body exposure of both males and females to 478 mg/m3 of NMP vapour for 6 h/day, 7 days/week, for a minimum of 100 days (pre-mating, mating, gestation, and lactation periods) resulted in a 7% decrease in fetal weight in the F1 offspring. A 4-11% transient, non-dose-dependent decrease was observed in the average pup weight at all exposure levels tested (41, 206, and 478 mg/m3).

Developmental toxicity: When NMP was administered dermally, developmental toxicity was registered in rats at 750 mg/kg body weight. The observed effects were increased preimplantation losses, decreased fetal weights, and delayed ossification. The NOAEL for both developmental effects and maternal toxicity (decreased body weight gain) was 237 mg/kg body weight. Inhalation studies in rats (whole-body exposure) demonstrated developmental toxicity as increased preimplantation loss without significant effect on implantation rate or number of live fetuses at 680 mg/m3 and behavioural developmental toxicity at 622 mg/m3. In an inhalation study (whole-body exposure), the NOAEL for maternal effects was 100 mg/m3, and the NOAEL for developmental effects was 360 mg/m3.

A tolerable inhalation concentration, 0.3 mg/m3, based on mortality and organ damage, is expected to be protective against any possible reproductive toxicity. Similarly, an oral tolerable intake of 0.6 mg/kg body weight per day, based on a 90-day study, is expected to provide adequate protection against possible reproductive effects. Because of non-existent data on the exposure of the general population and very limited information on occupational exposure, no meaningful risk characterisation can be performed

A substance (or part of a group of chemical substances) of very high concern (SVHC) - or product containing an SVHC: It is proposed that use within the European Union be subject to authorisation under the REACH Regulation. Indeed, listing of a substance as an SVHC by the European Chemicals Agency (ECHA) is the first step in the procedure for authorisation or restriction of use of a chemical.

The criteria are given in article 57 of the REACH Regulation. A substance may be proposed as an SVHC if it meets one or more of the following criteria:

- it is carcinogenic *;
- it is mutagenic *;
- it is toxic for reproduction *;
- it is persistent, bioaccumulative and toxic (PBT substances);
- it is very persistent and very bioaccumulative (vPvB substances):
- there is "scientific evidence of probable serious effects to human health or the environment which give rise to an equivalent level of concern"; such substances are identified on a case-by-case basis.
- * Collectively described as CMR substances

The "equivalent concern" criterion is significant because it is this classification which allows substances which are, for example, neurotoxic, endocrine-disrupting or otherwise present an unanticipated environmental health risk to be regulated under REACH] Simply because a substance meets one or more of the criteria does not necessarily mean that it will be proposed as an SVHC. Many such substances are already subject to restrictions on their use within the European Union, such as those in Annex XVII of the REACH Regulation SVHCs are substances for which the current restrictions on use (where these exist) might be insufficient. There are three priority groups for assessment:

- ► PBT substances and vPvB substances;
- substances which are widely dispersed during use;
- substances which are used in large quantities.

For petroleum: This product contains benzene, which can cause acute myeloid leukaemia, and n-hexane, which can be metabolized to compounds which are toxic to the nervous system. This product contains toluene, and animal studies suggest high concentrations of toluene lead to hearing loss. This product contains ethyl benzene and naphthalene, from which animal testing shows evidence of tumour formation.

Cancer-causing potential: Animal testing shows inhaling petroleum causes tumours of the liver and kidney; these are however not considered to be relevant in humans.

AROMATIC 150

Mutation-causing potential: Most studies involving gasoline have returned negative results regarding the potential to cause mutations, including all recent studies in living human subjects (such as in petrol service station attendants).

Reproductive toxicity: Animal studies show that high concentrations of toluene (>0.1%) can cause developmental effects such as lower birth weight and developmental toxicity to the nervous system of the foetus. Other studies show no adverse effects on the foetus.

Human effects: Prolonged or repeated contact may cause defatting of the skin which can lead to skin inflammation and may make the skin more susceptible to irritation and penetration by other materials.

Animal testing shows that exposure to gasoline over a lifetime can cause kidney cancer, but the relevance in humans is questionable.

Issue Date: **27/10/2023**Print Date: **16/02/2024**

CLODINAFOP-PROPARGYL & CLOQUINTOCET-MEXYL

The following information refers to contact allergens as a group and may not be specific to this product. Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody-mediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested.

N-METHYL-2-PYRROLIDONE & AROMATIC 150

Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production.

Acute Toxicity	~	Carcinogenicity	×
Skin Irritation/Corrosion	~	Reproductivity	×
Serious Eye Damage/Irritation	~	STOT - Single Exposure	×
Respiratory or Skin sensitisation	~	STOT - Repeated Exposure	✓
Mutagenicity	×	Aspiration Hazard	~

Legend: X − Data either not available or does not fill the criteria for classification

✓ – Data available to make classification

SECTION 12 Ecological information

Toxicity

	Endpoint	Test Duration (hr)		Species		Value	Source
AC Tussel	Not Available	Not Available No		Not Available Not Available		Not Available	Not Available
	Endpoint	Test Duration (hr)	Sp	ecies	Value		Source
	EC50	96h	Alg	ae or other aquatic plants	2.727-	100.575mg/L	4
	EC50	48h	Cru	ustacea	>74mg	/I	Not Available
clodinafop-propargyl	EC50	72h	Alg	ae or other aquatic plants	5.225-	11.354mg/L	4
	EC50(ECx)	48h	Cru	ustacea	>74mg	/I	Not Available
	LC50	96h Fish		0.39ოდ	0.39mg/l		
	Endpoint	Test Duration (hr)		Species		Value	Source
	ErC50	72h		Algae or other aquatic plants		5.3mg/l	2
	EC50	48h		Crustacea		>0.82mg/l	2
cloquintocet-mexyl	EC50	96h		Algae or other aquatic plants		>0.24mg/l	2
	EC50	72h Al		Algae or other aquatic plants		0.42mg/l	2
	NOEC(ECx)	504h Crusta		Crustacea	Crustacea 0.002mg/		2
	LC50	96h Fish		Fish		>0.97mg/l	2
	Endpoint	Test Duration (hr)		Species		Value	Source
	EC50	48h		Crustacea		ca.4897mg/l	1
N-methyl-2-pyrrolidone	EC50	72h		Algae or other aquatic plants		>500mg/l	1
	NOEC(ECx)	504h		Crustacea		12.5mg/l	2
	LC50	96h		Fish		464mg/l	1

Issue Date: **27/10/2023**Print Date: **16/02/2024**

	Endpoint	Test Duration (hr)	Species	Value	Source
	EC50	48h	Crustacea	0.95mg/l	1
	EC50	96h	Algae or other aquatic plants	11.7mg/l	2
	EC50(ECx)	48h	Crustacea	0.95mg/l	1
	EC50	72h	Algae or other aquatic plants	<1mg/l	1
aromatic 150	LC50	96h	Fish	2-5mg/l	Not Available
	EC50	48h	Crustacea	6.14mg/l	1
	EC50	96h	Algae or other aquatic plants	64mg/l	2
	NOEC(ECx)	72h	Algae or other aquatic plants	1mg/l	1
	EC50	72h	Algae or other aquatic plants	19mg/l	1
Legend:	Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data				

Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
clodinafop-propargyl	HIGH	HIGH
cloquintocet-mexyl	HIGH	HIGH
N-methyl-2-pyrrolidone	LOW	LOW

Bioaccumulative potential

Ingredient	Bioaccumulation
clodinafop-propargyl	HIGH (LogKOW = 4.8499)
cloquintocet-mexyl	HIGH (LogKOW = 5.672)
N-methyl-2-pyrrolidone	LOW (BCF = 0.16)
aromatic 150	LOW (BCF = 159)

Mobility in soil

Ingredient	Mobility
clodinafop-propargyl	LOW (KOC = 13740)
cloquintocet-mexyl	LOW (KOC = 38070)
N-methyl-2-pyrrolidone	LOW (KOC = 20.94)

SECTION 13 Disposal considerations

Waste treatment methods

Product / Packaging disposal

- ▶ Recycle wherever possible or consult manufacturer for recycling options.
- ► Consult State Land Waste Authority for disposal.
- ▶ Bury or incinerate residue at an approved site.
- ▶ Recycle containers if possible, or dispose of in an authorised landfill.

SECTION 14 Transport information

Labels Required







HAZCHEM •3Z

Land transport (ADG)

14.1. UN number or ID number	3082		
14.2. UN proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (contains clodinafop-propargyl)		
14.3. Transport hazard class(es)	Class Subsidiary Hazard	9 Not Applicable	
14.4. Packing group	III		
14.5. Environmental hazard	Environmentally hazardous		
14.6. Special precautions for user	Special provisions Limited quantity	274 331 335 375 AU01 5 L	

Environmentally Hazardous Substances meeting the descriptions of UN 3077 or UN 3082 are not subject to this Code when transported by road or rail in;

- (a) packagings;
- (b) IBCs; or
- (c) any other receptacle not exceeding 500 kg(L).
- Australian Special Provisions (SP AU01) ADG Code 7th Ed.

Air transport (ICAO-IATA / DGR)

14.1. UN number	3082			
14.2. UN proper shipping name	Environmentally hazardous substance, liquid, n.o.s. (contains clodinafop-propargyl)			
14.3. Transport hazard class(es)	ICAO/IATA Class	9		
	ICAO / IATA Subsidiary Hazard	Not Applicable		
	ERG Code	9L		
14.4. Packing group	III			
14.5. Environmental hazard	Environmentally hazardous			
	Special provisions		A97 A158 A197 A215	
	Cargo Only Packing Instructions		964	
	Cargo Only Maximum Qty / Pack		450 L	
14.6. Special precautions for user	Passenger and Cargo Packing Instructions		964	
	Passenger and Cargo Maximum Qty / Pack		450 L	
	Passenger and Cargo Limited Quantity Packing Instructions		Y964	
	Passenger and Cargo Limited Maximum Qty / Pack		30 kg G	
	<u> </u>		,	

Sea transport (IMDG-Code / GGVSee)

14.1. UN number	3082	
14.2. UN proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (contains clodinafop-propargyl)	
14.3. Transport hazard class(es)	IMDG Class IMDG Subsidiary Hazard	9 Not Applicable
14.4. Packing group	III	
14.5 Environmental hazard	Marine Pollutant	

Issue Date: 27/10/2023 Print Date: 16/02/2024

14.6. Special precautions for user

EMS Number	F-A, S-F	
Special provisions	274 335 969	
Limited Quantities	5 L	

14.7.1. Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

14.7.2. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
clodinafop-propargyl	Not Available
cloquintocet-mexyl	Not Available
N-methyl-2-pyrrolidone	Not Available
aromatic 150	Not Available

14.7.3. Transport in bulk in accordance with the IGC Code

Product name	Ship Type
clodinafop-propargyl	Not Available
cloquintocet-mexyl	Not Available
N-methyl-2-pyrrolidone	Not Available
aromatic 150	Not Available

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

clodinafop-propargyl is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals

 $\label{thm:condition} \textbf{Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule \ 6}$

cloquintocet-mexyl is found on the following regulatory lists

Not Applicable

N-methyl-2-pyrrolidone is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6

Australian Inventory of Industrial Chemicals (AIIC)

Chemical Footprint Project - Chemicals of High Concern List

aromatic 150 is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals

Australian Inventory of Industrial Chemicals (AIIC)

Chemical Footprint Project - Chemicals of High Concern List

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Not Classified as Carcinogenic

Additional Regulatory Information

Not Applicable

National Inventory Status

National Inventory	Status	
Australia - AIIC / Australia Non-Industrial Use	No (clodinafop-propargyl; cloquintocet-mexyl)	
Canada - DSL	No (clodinafop-propargyl; cloquintocet-mexyl)	
Canada - NDSL	No (clodinafop-propargyl; cloquintocet-mexyl; N-methyl-2-pyrrolidone; aromatic 150)	
China - IECSC	No (clodinafop-propargyl)	

National Inventory	Status	
Europe - EINEC / ELINCS / NLP	No (clodinafop-propargyl; cloquintocet-mexyl)	
Japan - ENCS	No (clodinafop-propargyl; cloquintocet-mexyl)	
Korea - KECI	No (clodinafop-propargyl; cloquintocet-mexyl)	
New Zealand - NZIoC	Yes	
Philippines - PICCS	No (clodinafop-propargyl; cloquintocet-mexyl)	
USA - TSCA	No (clodinafop-propargyl)	
Taiwan - TCSI	Yes	
Mexico - INSQ	No (clodinafop-propargyl; cloquintocet-mexyl)	
Vietnam - NCI	Yes	
Russia - FBEPH	No (clodinafop-propargyl; cloquintocet-mexyl)	
Legend:	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.	

SECTION 16 Other information

Revision Date	27/10/2023
Initial Date	01/11/2009

SDS Version Summary

Version	Date of Update	Sections Updated
8.1	10/03/2023	Classification change due to full database hazard calculation/update.
9.1	27/10/2023	UN Number update

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

- ▶ PC TWA: Permissible Concentration-Time Weighted Average
- PC STEL: Permissible Concentration-Short Term Exposure Limit
- ► IARC: International Agency for Research on Cancer
- ▶ ACGIH: American Conference of Governmental Industrial Hygienists
- ▶ STEL: Short Term Exposure Limit
- ► TEEL: Temporary Emergency Exposure Limit。
- ▶ IDLH: Immediately Dangerous to Life or Health Concentrations
- ► ES: Exposure Standard
- ► OSF: Odour Safety Factor
- NOAEL: No Observed Adverse Effect Level
- ► LOAEL: Lowest Observed Adverse Effect Level
- ► TLV: Threshold Limit Value
- LOD: Limit Of Detection
- ► OTV: Odour Threshold Value
- ▶ BCF: BioConcentration Factors
- ▶ BEI: Biological Exposure Index
- ► DNEL: Derived No-Effect Level
- ▶ PNEC: Predicted no-effect concentration
- ▶ AIIC: Australian Inventory of Industrial Chemicals
- ► DSL: Domestic Substances List
- ▶ NDSL: Non-Domestic Substances List
- ► IECSC: Inventory of Existing Chemical Substance in China
- ▶ EINECS: European INventory of Existing Commercial chemical Substances
- ▶ ELINCS: European List of Notified Chemical Substances
- ► NLP: No-Longer Polymers

Chemwatch: 26-0743 Version No: 9.1 **AC Tussel**

Page 17 of 17

Issue Date: 27/10/2023 Print Date: 16/02/2024

- ► ENCS: Existing and New Chemical Substances Inventory
- ▶ KECI: Korea Existing Chemicals Inventory
- ▶ NZIoC: New Zealand Inventory of Chemicals
- ▶ PICCS: Philippine Inventory of Chemicals and Chemical Substances
- ► TSCA: Toxic Substances Control Act
- ► TCSI: Taiwan Chemical Substance Inventory
- ▶ INSQ: Inventario Nacional de Sustancias Químicas
- ► NCI: National Chemical Inventory
- ▶ FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.